CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 21-28

  Amatya, Vishwa Jeet ^a   Takeshima, Yukio ^c   Aoe, Keisuke ^b   Fujimoto, Nobukazu ^c   Okamoto, Toshihiro ^d   Yamada, Taketo ^e   Kishimoto, Takumi ^c   Morimoto, Chikao ^d   Inai, Kouki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NATIONAL SANYO HOSPITAL   (Japan)

^c OKAYAMA ROSAI HOSPITAL   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e KEIO UNIVERSITY   (Japan)

Author keywords

CD9 immunohistochemistry; CD9 shRNA; Mesothelioma; Migration; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CD9 ANTIGEN; PEMETREXED;

ADULT; AGE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; CLINICAL FEATURE; CONTROLLED STUDY; EPITHELIOID MESOTHELIOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SARCOMATOID MESOTHELIOMA; SURVIVAL RATE;

ANTIGENS, CD9; CELL ADHESION; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROGNOSIS; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84872873243     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2116     Document Type: Article

References (28)

1. Tarrant JM, Robb L, van Spriel AB and Wright MD: Tetraspanins: molecular organisers of the leukocyte surface. Trends Immunol 24: 610-617, 2003.
2. Zoller M: Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 9: 40-55, 2009.
3. Nakamoto T, Murayama Y, Oritani K, et al: A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J Gastroenterol 44: 889-896, 2009.
4. Ghani FI, Yamazaki H, Iwata S, et al: Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem Biophys Res Commun 404: 735-742, 2011.
5. Milano MT and Zhang H: Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol 5: 1841-1848, 2010.
6. Kobayashi N, Toyooka S, Yanai H, et al: Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer 62: 120-125, 2008.
7. Nojiri S, Gemba K, Aoe K, et al: Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol 41: 32-39, 2011.
8. Gaafar R, Bahnassy A, Abdelsalam I, et al: Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer 70: 43-50, 2010.
9. Rena O, Boldorini LR, Gaudino E and Casadio C: Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations. J Surg Oncol 104: 701-705, 2011.
10. Hirayama N, Tabata C, Tabata R, et al: Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir Med 105: 137-142, 2011.
11. Tabata C, Hirayama N, Tabata R, et al: A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma. Eur Respir J 36: 1099-1105, 2010.
12. Pinton G, Brunelli E, Murer B, et al: Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res 69: 4598-4604, 2009.
13. Fischer JR, Ohnmacht U, Rieger N, et al: Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 54: 109-116, 2006.
14. Pass HI, Goparaju C, Ivanov S, et al: hsa-miR-29c is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 70: 1916-1924, 2010.
15. Travis W, Brambilla E, Müller-Hermelink H and Harris C (eds): World Health Organization Classification of Tumours: Pathology & Genetics. Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004.
16. Amatya VJ, Takeshima Y, Kushitani K, Yamada T, Morimoto C and Inai K: Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma. Oncol Rep 26: 1369-1375, 2011.
17. Ikeyama S, Koyama M, Yamaoko M, Sasada R and Miyake M: Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 177: 1231-1237, 1993.
18. Miyake M, Koyama M, Seno M and Ikeyama S: Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J Exp Med 174: 1347-1354, 1991.
19. Higashiyama M, Doi O, Kodama K, et al: Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int J Cancer 74: 205-211, 1997.
20. Mori M, Mimori K, Shiraishi T, et al: Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res 4: 1507-1510, 1998.
21. Jamil F, Peston D and Shousha S: CD9 immunohistochemical staining of breast carcinoma: unlikely to provide useful prognostic information for routine use. Histopathology 39: 572-577, 2001.
22. Sho M, Adachi M, Taki T, et al: Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int J Cancer 79: 509-516, 1998.
23. Wang JC, Begin LR, Berube NG, et al: Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications. Clin Cancer Res 13: 2354-2361, 2007.
24. Okochi H, Mine T, Nashiro K, Suzuki J, Fujita T and Furue M: Expression of tetraspans transmembrane family in the epithelium of the gastrointestinal tract. J Clin Gastroenterol 29: 63-67, 1999.
25. Buim ME, Lourenco SV, Carvalho KC, et al: Downregulation of CD9 protein expression is associated with aggressive behavior of oral squamous cell carcinoma. Oral Oncol 46: 166-171, 2010.
26. Mhawech P, Herrmann F, Coassin M, Guillou L and Iselin CE: Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression. Cancer 98: 1649-1657, 2003.
27. Higashiyama M, Taki T, Ieki Y, et al: Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res 55: 6040-6044, 1995.
28. Kohmo S, Kijima T, Otani Y, et al: Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer. Cancer Res 70: 8025-8035, 2010.